// App-Quantinova.ai

e15094 : Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.

Researchers

Presenter

  • Niels Halama

Principal Investigators

  • Ulrike Pruefer

  • Anna Fromming

  • Diana Beyer

  • Dirk Eulberg

  • Jarl Ulf Jungnelius

  • Aram Mangasarian

Medical Centers

  • Heidelberg University Hospital, Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany

  • National Center for Tumor Diseases DKFZ, Heidelberg, Germany

  • NOXXON Pharma AG, Berlin, Germany

  • NOXXON Pharma AG, Heidelberg, Germany

  • NOXXON Pharma AG, Berlin, DE

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Stromal cell-derived factor 1

Drug/Treatment

  • Pembrolizumab

  • NOX A12

  • CXCL12

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT03168139

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved